How to buy SpringWorks Therapeutics (SWTX) stock

SpringWorks Therapeutics, Inc is a biotechnology business based in the US. SpringWorks Therapeutics shares (SWTX) are listed on the NASDAQ and all prices are listed in US Dollars. SpringWorks Therapeutics employs 98 staff and has a trailing 12-month revenue of around 0.00.

SpringWorks Therapeutics stock price (NASDAQ: SWTX)

Use our graph to track the performance of SWTX stocks over time.

SpringWorks Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-23.

Latest market close	$85.55
52-week range	$35.20 - $96.48
50-day moving average	$81.95
200-day moving average	$77.58
Wall St. target price	$110.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-44.68

Buy SpringWorks Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy SpringWorks Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of SpringWorks Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

SpringWorks Therapeutics price performance over time

Historical closes compared with the close of $85.55 from 2021-06-08

1 week (2021-07-14)	N/A
1 month (2021-06-25)	0.78%
3 months (2021-04-21)	N/A
6 months (2021-01-21)	N/A

1 year (2020-07-21)	N/A
2 years (2019-07-21)	N/A
3 years (2018-07-21)	N/A
5 years (2016-07-21)	N/A

SpringWorks Therapeutics financials

Revenue TTM	$35 million
Gross profit TTM	$35 million
Return on assets TTM	-8.59%
Return on equity TTM	-14.25%
Profit margin	-171.62%
Book value	$11.06
Market capitalisation	$4 billion

TTM: trailing 12 months

Shorting SpringWorks Therapeutics shares

There are currently 3.5 million SpringWorks Therapeutics shares held short by investors – that's known as SpringWorks Therapeutics's "short interest". This figure is 1.5% down from 3.5 million last month.

There are a few different ways that this level of interest in shorting SpringWorks Therapeutics shares can be evaluated.

SpringWorks Therapeutics's "short interest ratio" (SIR)

SpringWorks Therapeutics's "short interest ratio" (SIR) is the quantity of SpringWorks Therapeutics shares currently shorted divided by the average quantity of SpringWorks Therapeutics shares traded daily (recently around 263732.72589218). SpringWorks Therapeutics's SIR currently stands at 13.17. In other words for every 100,000 SpringWorks Therapeutics shares traded daily on the market, roughly 13170 shares are currently held short.

However SpringWorks Therapeutics's short interest can also be evaluated against the total number of SpringWorks Therapeutics shares, or, against the total number of tradable SpringWorks Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case SpringWorks Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 SpringWorks Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.1363% of the tradable shares (for every 100,000 tradable SpringWorks Therapeutics shares, roughly 136 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against SpringWorks Therapeutics.

Find out more about how you can short SpringWorks Therapeutics stock.

SpringWorks Therapeutics share dividends

We're not expecting SpringWorks Therapeutics to pay a dividend over the next 12 months.

SpringWorks Therapeutics overview

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin -blmf, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in Phase 1 clinical trial for the treatment of RRMM. In addition, it is developing Nirogacestat + teclistamab, which is in clinical stage that targets BCMA and CD3; Nirogacestat + elranatamab; Nirogacestat + PBCAR269A, which is in Phase 1/2a clinical trial for allogeneic BCMA CAR T cell therapy; Mirdametinib that is in Phase 1/2a clinical trial for the treatment of NF1-PN; Mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd. , GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc.

Frequently asked questions

What percentage of SpringWorks Therapeutics is owned by insiders or institutions?
Currently 13.422% of SpringWorks Therapeutics shares are held by insiders and 92.434% by institutions. How many people work for SpringWorks Therapeutics?
Latest data suggests 98 work at SpringWorks Therapeutics. When does the fiscal year end for SpringWorks Therapeutics?
SpringWorks Therapeutics's fiscal year ends in December. Where is SpringWorks Therapeutics based?
SpringWorks Therapeutics's address is: 100 Washington Boulevard, Stamford, CT, United States, 06902 What is SpringWorks Therapeutics's ISIN number?
SpringWorks Therapeutics's international securities identification number is: US85205L1070 What is SpringWorks Therapeutics's CUSIP number?
SpringWorks Therapeutics's Committee on Uniform Securities Identification Procedures number is: 844909101